Phosphorylation of islet-1 serine 269 by CDK1 increases its transcriptional activity and promotes cell proliferation in gastric cancer

Qiong Shi1, Xiaomei Ni1, Ming Lei1, Quansong Xia1, Yan Dong2, Qiao Zhang3 and Weiping Wang4*

Abstract

Background: Despite recent advances in diagnostic and therapeutic approaches for gastric cancer (GC), the survival of patients with advanced GC remains very low. Islet-1 (ISL1) is a LIM-homeodomain transcription factor, which is upregulated and promotes cell proliferation in GC. The exact mechanism by which ISL1 influences GC development is unclear.

Methods: Co-immunoprecipitation (co-IP) and glutathione S-transferase (GST)-pulldown assays were employed to evaluate the interaction of ISL1 with CDK1. Western blot and immunohistochemistry analyses were performed to evaluate the ability of CDK1 to phosphorylate ISL1 at Ser 269 in GC cell and tissue specimens. Chromatin immunoprecipitation (ChIP), ChIP re-IP, luciferase reporter, and CCK-8 assays were combined with flow cytometry cell cycle analysis to detect the transactivation potency of ISL1-S269-p and its ability to promote cell proliferation. The self-stability and interaction with CDK1 of ISL1-S269-p were also determined.

Results: ISL1 is phosphorylated by CDK1 at serine 269 (S269) in vivo. Phosphorylation of ISL1 by CDK1 on serine 269 strengthened its binding on the cyclin B1 and cyclin B2 promoters and increased its transcriptional activity in GC. Furthermore, CDK1-dependent phosphorylation of ISL1 correlated positively with ISL1 protein self-stability in NIH3T3 cells.

Conclusions: ISL1-S269-p increased ISL1 transcriptional activity and self-stability while binding to the cyclinB1 and cyclinB2 promoters promotes cell proliferation. ISL1-S269-p is therefore crucial for tumorigenesis and potentially a direct therapeutic target for GC.

Keywords: ISL1, Phosphorylation, CDK1, Transcription activity, Gastric cancer

Introduction

Gastric cancer (GC) is the fifth most common malignancy and the third leading cause of cancer-related deaths (Ferlay et al. 2015). China is among the countries with the highest incidence of GC, accounting for over 40% of all new cases of GC worldwide (Bu and Ji 2013). Despite recent advances in diagnostic modalities and the development of molecular-targeted drugs, the survival rates of patients with advanced GC remains very low (Waddell et al. 2013). Understanding the precise molecular mechanisms underlying GC progression is therefore crucial for the development of effective therapeutic strategies against GC.

ISL1 or human insulin gene enhancer binding protein 1 (islet-1) is a LIM homeodomain transcription factor encoded by the ISL1 gene (Karlsson et al. 1990), and

*Correspondence: wwp@bjmu.edu.cn
4 Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Beijing Key Laboratory of Protein Posttranslational Modifications and Cell Function, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education of China, Peking University, Beijing, P. R. China

Full list of author information is available at the end of the article
functions as a transcription factor that regulates the expression of genes involved in heart, motor neuron, and pancreas development and foregut morphogenesis (Bu et al. 2009; Guo et al. 2011; Kim et al. 2019; Shi et al. 2009; Zhang et al. 2018). ISL1 is a marker for pancreatic neuroendocrine tumors and their metastases (Dong et al. 1991; Wang et al. 2014). We previously reported that ISL1 is highly expressed in GC and is correlated with advanced tumor-nodes-metastasis (TNM) stage, lymph node metastasis, and poorer overall survival (Guo et al. 2015). Further, ISL1 could activate cyclinB1, cyclinB2, and c-myc expression in GC cells by directly binding to conserved binding sites on their promoter or enhancer, and thereby promote GC cell proliferation (Shi et al. 2016). However, the exact mechanisms by which ISL1 modulates GC development remain unknown. Understanding the roles of this protein in GC development and the ways in which it could be modulated could be of great research and clinical interest.

Post-translational phosphorylation plays critical roles in the assembly of signaling and repair proteins in several biological progresses (Sharma et al. 2014). Although several phosphorylation sites such as T182 (Zahedi et al. 2008) and S221 (Mertins et al. 2013; Sharma et al. 2014) have been identified in ISL1 proteins, but the molecular mechanisms that govern their physiological effects remain unclear. Further, ISL1 overexpression or knockdown leads to increased or decreased GC cell proliferation, respectively, and can influence cell cycle transition (Guo et al. 2019; Shi et al. 2016). CDK1 is a major cell cycle transition kinase (McDonald et al. 2020); we therefore investigated whether ISL1 is regulated by CDK1.

In this study, we aimed to elucidate the molecular interactions of endogenous ISL1 with CDK1 in GC cell lines. Our results showed that CDK1 phosphorylated ISL1 Ser-269, which promoted its transcriptional activity and increased protein self-stability. The S269 ISL1-CDK1 complex increased the proliferation in GC cells. Collectively, our results provide the first evidence that CDK1 phosphorylates ISL1 Ser-269, and provides insights into the role of ISL1 in GC.

Methods and materials

Cell lines and culture

The GC cell line BGC823 (ICLC: HTL98007), was purchased from Instituto Nazionale per la Ricerca sul Cancro (ICLC, Genova, Italy). MGC803, MKN28, and an immortalized human gastric epithelial cell line,GES1, were gifts from Profs. Shou CC and Ke Y (Peking University Cancer Hospital). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 80 U/ml penicillin, and 100 mg/ml streptomycin at 37 °C under 5% CO2.

Immunoprecipitation and western blot analysis

Cell lysates were prepared using radioimmunoprecipitation assay (RIPA) lysis buffer (P0013E; Beyotime, Shanghai, China) supplemented with protease inhibitor cocktail (469,313,200; Roche, Basle, Switzerland). Immunoprecipitation and western blot analysis were carried out as described previously (Liu et al. 2009), with ISL1 for Co-IP (H00003670-M05, Abnova, Taipei, China) and ISL1 for western blotting (ab109517, Abcam). Monoclonal anti-CDK1 (#9116), GAPDH (#2118), rabbit polyclonal anti-CDK1-T161P (#9114), and mouse monoclonal anticyclin B1 (#4135) were purchased from Cell Signaling Technology (Danvers, MA, USA). Mouse monoclonal anti-phosphoserine (05-1000) was obtained from Merck Millipore (Millipore Corp, Billerica, MA, USA). Rabbit polyclonal antibody against the phosphorylation site of ISL1 at Ser 269 (ISL1-S269) (1:1,000) was produced with the synthetic phosphopeptide MTGTPMVAA[Sp]PERHDGGLQ (Absin Bioscience Inc., Shanghai, China).

Glutathione S-transferase (GST) pull-down assay

GST fused with full-length ISL-1 or various truncated ISL-1 proteins were prepared as described previously (Zhang et al. 2009). Biotin-labeled wild-type CDK1 was synthesized using the TNT Quick Coupled Transcription/Translation System (L5020, Promega, Madison, WI, USA) (Wang et al. 2016).

Immunohistochemistry (IHC)

All human GC tissue specimens (35 poorly differentiated adenocarcinoma, 22 moderately differentiated adenocarcinoma, 3 well-differentiated adenocarcinoma) were obtained from the Pathology Department, School of Clinical Oncology, Kunming Medical University (China). IHC was performed on 5-mm-thick serial sections of formaldehyde-fixed, paraffin-embedded tissue blocks derived from GC with paired adjacent tissue. The sections were incubated overnight at 4 °C with an antibody against ISL1 phosphorylated at Ser 269 (ISL1-S269) (1:150) produced using the synthetic phosphopeptide MTGTPMVAA[Sp]PERHDGGLQ (Absin Bioscience Inc., Shanghai, China). The extent of staining was defined as follows: 0%: -, 1–24%: +, 25–49%: ++, 50–74%: ++++, and 75–100%: +++++.

Chromatin immunoprecipitation (ChiP) and ChiP re-IP assays

ChiP and ChiP re-IP experiments were performed in MKN28 and MGC803 cells as previously described (Zhang et al. 2007). After elution, real-time PCR or conventional PCR were performed to amplify the
DNA fragment containing the \textit{CCNB1} or \textit{CCNB2} promoters, covering the ISL1/CDK1 binding sites, with the primers listed in Table 1.

**Table 1** Primer sequences

| Gene       | Primer sequences (5′–3′)                          |
|------------|---------------------------------|
| CCNB1      | Sense: CCGCTTCGGACTGGGAACCTAA  |
|            | Antisense: AGAGCAGGAGCAAGCTAAGG |
| CCNB2      | Sense: GCGGTATTTGATTCCTGGAGGACAG |
|            | Antisense: CGGACTGAAAGGGAGGACT   |

**Table 2** RNAi duplex sequences

| Gene   | RNAi duplex Sequences (5′–3′)                          |
|--------|---------------------------------|
| CDK1-1 | Sense: CCAUAGAUUCGAAGAAAU dTdT |
|        | Antisense: dTdT GGUACCCAGACUUUUUAU |
| CDK1-2 | Sense: GCCAGAGUGAAGAUCUUUUU dTdT |
|        | Antisense: dTdT CGGUCUACCUCCUAAGAAU |
| CDK1-3 | Sense: UCCGGAUUUGUUCUUAUUA dTdT |
|        | Antisense: dTdT AGGCCUUAAGAGAUAU |
|        | Antisense: ACCUGACAGCUUGAGGAAT |

**Plasmid transfection and RNA interference**

Cells were transfected with plasmids or synthesized siRNA for gene overexpression or knockdown, respectively. The plasmid constructs pcDNA3.1-ISL1, control pcDNA3.1, pLL3.7-ISL1-siRNA (si-ISL1), and control pLL3.7-Non-silencer have been previously described (Guo et al. 2011). The pcDNA3.1-ISL1-S269A plasmid was constructed by TransGen Biotech (Beijing, China). DNA plasmids encoding CDK1 (Addgene plasmid #1886) and CDK1-DN (Addgene plasmid #1887) were obtained from Addgene. Site-directed mutagenesis was commercially performed by GeneChem (Beijing, China), and Ser 269 in ISL1 was replaced with alanine. Transfection of the plasmids and siRNA was carried out using LipofectamineTM2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocols. After 48 h of transfection, cells were harvested. All transfections were performed at least three times.

**Luciferase assay**

Plasmid transfection and luciferase activity detection were performed as described previously (Liu et al. 2011). The cyclinB1-luc and cyclinB2-luc reporters were constructed by TransGen Biotech (Beijing, China).

**Cell proliferation assays**

The cell proliferation was assayed using CCK-8 as described previously (Guo et al. 2011).

**Flow cytometry cell cycle analysis**

For cell cycle analysis, cells were fixed in ice-cold 70% ethanol and incubated at 4 °C overnight. Fixed cells were washed with phosphate-buffered saline (PBS) and treated with 100 μg/ml RNase A at 37 °C for 20 min. After staining with propidium iodide (50 μg/ml), the cells were subjected to fluorescence-activated cell sorting (FACS) on a FACScan instrument (Becton Dickinson, Franklin Lakes, NJ, USA). Cell debris and fixation artifacts were gated out and cell populations at the G0/G1, S, and G2/M phases were quantified using the ModFit LT v2.0 software.

**Statistical analysis**

Data are expressed as the mean ± standard deviation (SD). All statistical analyses were conducted using SPSS (version 20; SPSS, Chicago, Illinois). \( \chi^2 \) tests and rank sum tests were used to evaluate the relationship between the ISL1-S629-p immune reaction and the clinicopathological features of the patients. Kaplan-Meier survival curves was generated to evaluate the effect of ISL1-S629-p on patient survival. For all statistical tests, the significance of differences between groups was determined using one-way analysis of variance (ANOVA). Differences were considered statistically significant at \( p < 0.05 \).

**Results**

**ISL1 interacts with CDK1 in vivo and in vitro**

In our previous study, we used mass spectrometry (Lu et al. 2015) to show that ISL1 interacts with CDK1 in MGC803 cell lines (high levels of ISL1 and higher proliferation rates) (Shi et al. 2016). Here, we determined whether ISL1 physically interacts with CDK1/cyclin B1 by using reciprocal co-immunoprecipitation. Our results indicated that these two molecules interact in vivo (Fig. 1a–c). We also used GST linked to ISL1 segments or GST alone to validate the interaction of CDK1 and ISL1 by using reciprocal co-immunoprecipitation. Our results suggested that ISL1 interacts directly with CDK1 (Fig. 1d).

**CDK1 mediates ISL1 phosphorylation at serine 269 in GC**

To determine whether ISL1 is phosphorylated, we performed co-immunoprecipitation using antibodies against phosphorylated serine and ISL1, and observed phosphorylation serine in ISL1 (Fig. 2a). We then sought to determine which residue in ISL1 could be phosphorylated by CDK1. CDKs often recognize and phosphorylate the serine/threonine-proline (S/T)PX(R/K) motif (Zhang et al.
2008). There is only one such motif (S269/P270) present in ISL1 (Fig. 2b), which matched with CDK phosphorylation consensus sites.

Next, we confirmed that CDK1 phosphorylates ISL1 at Ser 269 in vivo. We used a phospho-ISL1-Ser 269 antibody to immunoblot lysates from MGC803 cells transfected with plasmids encoding CDK1 or CDK1 siRNA. The endogenous level of phosphorylated ISL1 at Ser 269 increased when CDK1 was overexpressed, and CDK1 knockdown significantly reduced Ser 269 phosphorylation (Fig. 3a). Similar changes were also observed in the human gastric epithelial cell line GES1 (Additional file 2: Fig. S2). Furthermore, expression of dominant-negative mutant CDK1 (DN-CDK1) also decreased Ser 269 phosphorylation (Fig. 3b). ISL1 was visualized as two bands in the western blots of some samples. These two bands may represent the alternatively spliced variants, ISL1α and ISL1β, which have been reported previously (Ando et al. 2003). These results indicate that Ser 269 is phosphorylated by CDK1 in this cell line.

We replaced the Ser 269 residue with alanine (ISL1S269A), and transfected MKN28 cell lines (which have low levels of ISL1 and proliferate slowly) with wild-type or S269A-mutant ISL1. Phosphorylation of ISL1 was examined by immunoblotting with phospho-specific

Fig. 1  ISL1 interacts with CDK1. a–c Co-IP assays were performed to measure the ISL1/CDK1/cyclinB1 complex in MGC803 cells. Lysate was immunoprecipitated with antibodies against ISL1, CDK1, or cyclinB1 and analyzed by immunoblotting. IgG: immunoglobulin G. d Full-length or truncated ISL1 was used to construct GST-fusion proteins (Top) for pull-down assays with CDK1 protein (Bottom).

Fig. 2  ISL1 is serine-phosphorylated. a MGC803 cells lysates were immunoprecipitated (IP) using anti-ISL1 and analyzed by immunoblotting using antibody against phosphorylated serine and ISL1 (HC: heavy chain, LC: light chain). b Alignments of the cluster of ISL1; S269 fit the CDK1 phosphorylation consensus, and (S/T)PX(R/K) sequences (red shade) are shown.
antibody against phospho-S269. Forced expression of CDK1 increased S269 phosphorylation of wild-type ISL1 but not of S269A mutant (Fig. 3c, lane 2 versus lane 4). We also compared the phosphorylation levels of wild-type ISL1 and ISL1 S269A in MKN28 cells transfected with either wild-type (WT) or S269A-mutated ISL1 (S269A), and cultured without or with RO-3306 (10 μM, 20 h, Additional file 1: Fig. S1), a pan-CDK1 inhibitor (Vassilev et al. 2006). Decreased phosphorylation of Ser 269 was observed in cells expressing WT ISL1 cultured with RO-3306 (Fig. 3d, lane 2), with total ISL1 levels remaining constant. Our results indicated that CDK1 increased phosphorylation of Ser 269, and S269A mutation abolished CDK1-mediated phosphorylation of ISL1.
In this study, we confirmed the relationship between ISL1-S629-p expression and the overall survival time of patients with GC (35 poorly differentiated adenocarcinoma, 22 moderately differentiated adenocarcinoma, 3 well-differentiated adenocarcinoma) (Fig. 3e). The five-year survival rates of patients with ISL1-S629-p + + and ISL1-629-p+++ were 76 and 82%, respectively. There was no significant correlation between the expression of ISL1-S629-p and overall survival ($p = 0.524$) (Fig. 3f).

We also analyzed the relationship between expression of ISL1-S629-p and clinic pathological parameters of GC. Expression of ISL1-S629-p was not significantly correlated with sex, age, Tumor Node Metastasis (TNM) stages, and distant metastasis, but correlated negatively with the degree of invasion ($p = 0.021$) and differentiation of GC ($p = 0.010$) (Table 3).

### CDK1 phosphorylation of ISL1 promotes ISL1 binding on cyclinB1 and cyclinB2 promoters

ISL1 functions primarily as a transcription factor. Our next aim was therefore to determine whether the ISL1-CDK1/cyclin B1 complex binds to the promoters of the target genes $CCNB1$ and $CCNB2$ in MGC803 cells, by performing a ChIP assay. We found that ISL1-CDK1/cyclin B1 formed a transcriptional activation complex with the $CCNB1$ and $CCNB2$ promoters (Fig. 4a, b). Next, we determined whether CDK1-mediated ISL1 phosphorylation affects its transcriptional function. We analyzed ISL1 levels on the promoters of $CCNB1$ and $CCNB2$. Quantitative chromatin immunoprecipitation (qChIP) assay results showed lower levels of S269A-mutant ISL1 (S269A) that of wild-type (WT) on the $CCNB1$ and $CCNB2$ promoters (Fig. 4c, d). These results suggest that phosphorylation of ISL1 at Ser 269 by CDK1 strengthens ISL1 binding on the $CCNB1$ and $CCNB2$ promoters.

### Phosphorylation of ISL1 Ser 269 increases transactivation potency and promotes cell proliferation

We assayed the transactivation potency of wild-type (WT) or S269A-mutant ISL1 (S269A) by expressing each of these proteins in MKN28 cells along with plasmids encoding CDK1 or CDK1 inhibitor RO-3306. As shown in Fig. 5a, b, constitutive expression of either WT or CDK1/WT (Fig. 5a, b; second column versus fourth column) increased transcriptional activity of ISL1 in MKN28 cells. Similarly, S269A or WT/RO-3306 (Fig. 5a, b; third column versus sixth column) decreased the transcriptional activity of ISL1. Importantly, the enhancement of ISL1 by CDK1 was abrogated by the S269A mutation (Fig. 5a, b; fifth column versus seventh column). ISL1 enhances cell proliferation and cell cycle stimulation. We therefore investigated the effect of the S269A mutation on ISL1-mediated biological functions. By using stable transfects expressing wild-type ISL1 and ISL1 S269A in MKN28 cells, we observed significant differences in cell proliferation and cell cycle stimulation. Wild-type ISL1 and ISL1 S269A cells grew faster than did the control cells, and wild-type ISL1 cells grew faster than did ISL1 S269A cells at 48 h after transfection (Fig. 5c). Moreover, MKN28 cell cycle profiles showed that ISL1 S269A overexpression remarkably decreased the cell population in the G1 phase (from 57.94% ± 1.65 to 43.15% ± 2.92, $p<0.05$) and increased the cell population in the S and G2/M phases (from 42.05% ± 1.65 to 56.84% ± 2.92, $p<0.05$). This effect was significantly more enhanced by transfection with wild-type ISL1 (G1 phase from 57.94% ± 1.65 to 36.49% ± 3.48, S and G2/M phases from 42.05% ± 1.65 to 63.50% ± 3.48, $p<0.05$; Fig. 5d). Collectively, our results demonstrated that CDK1-induced phosphorylation of ISL1 Ser 269 is a critical positive regulator of cell proliferation and cell cycle transition.

### Table 3  Relationship between expression of ISL1-S629-p and clinic pathological parameters of gastric cancer

| Characteristic                  | ISL1-S629-p ++ (%) | ISL1-S629-p +++ (%) | p-value |
|--------------------------------|-------------------|---------------------|---------|
| Age                            |                   |                     |         |
| ≤ 60                           | 16 (55.2%)        | 10 (32.3%)          | 0.073   |
| > 60                           | 13 (44.8%)        | 21 (67.7%)          |         |
| Gender                         |                   |                     |         |
| Male                           | 19 (65.5%)        | 20 (64.5%)          | 0.935   |
| Female                         | 10 (34.5%)        | 11 (35.5%)          |         |
| Depth of invasion              |                   |                     |         |
| T1–2                           | 12 (41.4%)        | 22 (71.0%)          | 0.021   |
| T3–4                           | 17 (58.6%)        | 9 (29.0%)           |         |
| Lymph node metastasis          |                   |                     |         |
| N0                             | 10 (34.5%)        | 15 (48.4%)          | 0.275   |
| N1–3                           | 19 (65.5%)        | 16 (51.6%)          |         |
| Distant metastasis             |                   |                     |         |
| M0                             | 25 (86.2%)        | 28 (90.3%)          | 0.702   |
| M1                             | 4 (13.8%)         | 3 (9.7%)            |         |
| TNM stage                      |                   |                     |         |
| I                              | 7 (24.1%)         | 14 (45.2%)          | 0.309   |
| II                             | 10 (34.5%)        | 7 (22.6%)           |         |
| III                            | 9 (31.0%)         | 6 (19.4%)           |         |
| IV                             | 3 (10.3%)         | 4 (12.9%)           |         |
| Histological grade*            |                   |                     |         |
| G1                             | 1 (3.4%)          | 2 (6.5%)            | 0.010   |
| G2                             | 6 (20.7%)         | 16 (51.6%)          |         |
| G3                             | 22 (75.9%)        | 13 (41.9%)          |         |
To assess whether ISL1 phosphorylation mediates self-stability, NIH3T3 cells were transfected with wild-type ISL1 or ISL1 S269A for 48 h and treated with cycloheximide (CHX) to block protein synthesis for various lengths of time. Total cell lysates were prepared and immunoblotted. ISL1 S269A protein levels decreased within 6 h, and further reduced 10 h after CHX treatment, while wild-type ISL1 protein levels remained unchanged within 8 h after treatment with CHX (Fig. 6a).

We then studied the effect of CDK1 modification on ISL1-CDK1 combination. Nuclear extracts prepared from NIH3T3 cells transfected with CDK1 and either ISL1-WT, or ISL1-S269A for 48 h were subjected to Co-IP assay. We did not observe significant differences in ISL1-CDK1 binding (Fig. 6b). These data suggest that ISL1 phosphorylation increases self-stability but does not increase its interaction with CDK1.

Discussion

The expression and DNA methylation of ISL1 in carcinoma has been studied in many tumors (Dong et al. 1991; Erlenbach-Wunsch et al. 2014; Graham et al. 2013; Kim et al. 2013; Kitchen et al. 2015; Li et al. 2018; Wang et al. 2014; Zhang et al. 2014). We demonstrated previously that ISL1 expression may serve as a specific marker for GC treatment and prognosis (Guo et al. 2015). Further, ISL1 enhanced tumor growth and targeted the downstream genes CCNB1, CCNB2, and C-myc in GC (Shi et al. 2016). ISL1 was also positively associated with poor outcome in primary GC (Guo et al. 2019). However, the role of ISL1 in GC proliferation and carcinogenesis, and...
the mechanism by which ISL1 regulates proliferation and tumorigenesis remains unclear.

In this study, we found evidence that ISL1 interacts with CDK1 in vivo and in vitro. We first confirmed ISL1 interaction with CDK1 in MGC803 cells (which showed high levels of ISL1 and proliferated more quickly) by mass spectrometry. We then determined that ISL1 interacts with CDK1/cyclin and confirmed the interaction by using a GST pull-down assay to show that ISL1 interacts directly with CDK1.

Next, we demonstrated that CDK1 specifically phosphorylates ISL1 at S269, thereby promoting the transcriptional activity of ISL1. CDK1 is a serine/threonine kinase that is often dysregulated in human cancers including GC (Gao et al. 2014; Lee et al. 2016). The ISL1 C-terminal region also contains the LIM homeobox 3 (Lhx3)-binding domain (LBD), which is a candidate intramolecular interaction domain (Gadd et al. 2013). In addition, S269 in ISL1 fits the cyclin dependent kinase 1 (CDK1) phosphorylation consensus, (S/T)PX(R/K), and is the only such motif (S269/P270) present in ISL1, although mass spectrometry analysis is required to determine the phosphorylation status of Ser269 residue in ISL1 in vitro. We then used the phospho-ISL1-Ser 269 antibody for immunoblot analysis of the lysates from MGC803 cells transfected with plasmids encoding control vector and wild-type ISL1 or ISL1-S269A. The data represent 3 independent experiments, each performed in triplicate. Each bar represents mean ± SD. (*p < 0.05, WT vs. control, †p < 0.05, S269A vs. control, ‡p < 0.05, WT vs. S269A).

![Graphs and diagrams showing the effect of CDK1 activity on ISL1 transcriptional activity and cell proliferation](image)
cells GES1, and it was found that the overexpression or knockdown of CDK1 greatly affected the expression of ISL1 protein (Additional file 2: Fig. S2). This may be due to the low expression of ISL1 in GES1 and the regulation of phosphorylation is different from tumor cells. We then replaced the Ser 269 residue with alanine (ISL1S269A), transfected MKN28 cells (which had low levels of ISL1 and proliferated more slowly) with wild-type or S269A-mutated ISL1. CDK1 increased phosphorylation of the wild-type ISL1 but not of the S269A mutant. Because ISL1 functions primarily as a transcription factor and forms a complex to regulate target genes (Li et al. 2014; Li et al. 2014a, b). We determined whether the ISL1-CDK1/cyclin B1 complex binds to the promoters of the target genes CCNB1 and CCNB2. ChIP and quantitative chromatin immunoprecipitation (qChIP) assays showed that the ISL1-CDK1/cyclin B1 complex showed stronger localization on CCNB1 and CCNB2 promoters. This may result in positive feedback regulation by the ISL1-CDK1/cyclin B1/2 complex in GC (Fig. 6c), although this hypothesis remains to be investigated.

We further demonstrated that CDK1-mediated modification of ISL1 may contribute to tumorigenesis and proliferation via regulation of downstream genes in GC (Benanti 2016). Up- or downregulation of ISL1 in GC cells promoted cell cycle transition into the S/G2/M phases or cell cycle arrest in the G0/G1 phases respectively. More importantly, ISL1 regulated CCNB1 and CCNB2, and consequently influenced the cell cycle. We transfected wild-type (WT) or S269A-mutated ISL1 (S269A) into MKN28 cells along with plasmids encoding CDK1 or CDK1 inhibitor RO-3306. The WT or CDK1/WT cells showed increased transcriptional activity of ISL1. Similarly, S269A or WT/RO-3306 decreased the transcriptional activity of ISL1. Importantly, the stimulatory effect of CDK1 on ISL1 was abrogated by the S269A mutation. By using stable transfects expressing wild-type ISL1 and ISL1 S269A in MKN28 cells, we observed that wild-type ISL1 cells grew faster than did ISL1 S269A cells. Consistently, the MKN28 cell cycle profiles demonstrated that ISL1 S269A overexpression remarkably decreased the cell population in the G1 phase and increased the cell population in the S and G2/M phases. Importantly, this effect was significantly more increased by transfection with wild-type ISL1. We demonstrated that phosphorylation of Ser-269 strengthens the ability of ISL1 to activate transcription and stimulate proliferation. Thus, ISL1 activity is likely linked with the cell cycle via its regulation by cyclin-dependent kinase 1, through phosphorylation of distinct sites. These results indicate for the first time that the phosphorylation status of ISL1 is essential for sustained activation of ISL1 to promote cell proliferation via regulation of downstream genes. However, detection of the mechanism by which ISL1 is activated and targeted for degradation remain to be studied. Furthermore, the potential involvement of other molecules involved in the modification of ISL1 by CDK1 remains to be clarified.

Conclusions

We demonstrated that ISL1 interacts with CDK1, which phosphorylates ISL1 at Ser-269. ISL1-CDK1 showed improved binding on cyclin B1 and cyclin B2 promoters, and the phosphorylation increased ISL1 transcriptional activity and self-stability. It can be speculated that sustained activation of ISL1 promotes cell proliferation.
and tumorigenesis via a positive feedback mechanism (Fig. 6c). These findings provide, to our knowledge, the first evidence that CDK1 phosphorylates ISL1 Ser-269, and could provide a theoretical basis for the development of novel strategies and targets for GC treatment.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s10020-021-00302-6.

Acknowledgements

We appreciate all participants in this work.

Authors’ contributions

NXW and LW performed the experiments and prepared the manuscript; QXS and ZQ analyzed the data; DY performed the IHC analysis and cell cultures; SQ and WWP designed the experiments, participated in discussions and polished the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (No. 81760426, 81372363, 31300415), Yunnan Science and Technology Department Fund (2018FE001(-314)), (2018FE001(-315)).

Declarations

Ethical approval and consent to participate

This research was performed in accordance with amended Declaration of Helsinki, with the approval of the Kunming Medical University Research Ethics Committee.

Consent for publication

All authors give consent for publication.

Competing interests

The authors declare no conflicts of interest.

Author details

1 Clinical Laboratory, The Third Affiliated Hospital, Kunming Medical University & Yunnan Cancer Center, Yunnan, Kunming, P. R. China. 2 Pathology Department, The Third Affiliated Hospital, Kunming Medical University & Yunnan Cancer Center, Yunnan, Kunming, P. R. China. 3Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Kunming Medical University, Yunnan, Kunming, P. R. China. 4Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Beijing Key Laboratory of Protein Posttranslational Modifications and Cell Function, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education of China, Peking University, Beijing, P. R. China.

Received: 31 December 2020 Accepted: 14 April 2021

Published online: 07 May 2021

References

Ando K, Shioda S, Handa H, Kataoka K. Isolation and characterization of an alternatively spliced variant of transcription factor Islet-1. J Mol Endocrinol. 2003;31:419–25.
1. Liu Y, Li Y, Li T, Lu H, Jia Z, Wang W, Chen P, Ma K, Zhou C. POU homeodomain protein OCT1 modulates islet 1 expression during cardiac differentiation of P19CL6 cells. Cell Mol Life Sci. 2011;68:1969–82.

2. Lu D, Liu L, Ji X, Gao Y, Chen X, Liu Y, Liu Y, Zhao X, Li Y, Li Y, et al. The phosphatase DUSP2 controls the activity of the transcription activator STAT3 and regulates TH17 differentiation. Nat Immunol. 2015;16:1263–73.

3. McDonald IM, Grant GD, East MP, Gilbert TS, Willkerson EM, Goldfarb D, Beri J, Herring LE, Vaziri C, Cook JG, et al. Mass spectrometry-based selectivity profiling identifies a highly selective inhibitor of the kinase MLK that delays mitotic entry in cancer cells. J Biol Chem. 2020. https://doi.org/10.1074/jbc.RA119.011083.

4. Mertins P, Qiao JW, Patel J, Udeshi ND, Clauser KR, Mani DR, Burgess MW, Gillette MA, Jaffe JD, Carr SA. Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods. 2013;10:634–7.

5. Sharma K, D’Souza RC, Tyano S, Schaub C, Wisniewski JR, Cox J, Mann M. Ultra-deep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep. 2014;8:1583–94.

6. Shi Y, Zhao S, Li J, Mao B. Islet-1 is required for ventral neuron survival in Xenopus. Biochem Biophys Res Commun. 2009;388:506–10.

7. Shi Q, Wang W, Jia Z, Chen P, Ma K, Zhou C. ISL1, a novel regulator of CCNB1, CCNB2 and c-MYC genes, promotes gastric cancer cell proliferation and tumor growth. Oncotarget. 2016;7:36489–500.

8. Vassilev LT, Tovar C, Chen S, Knezevic D, Zhao X, Sun H, Heimbrook DC, Chen L. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc Natl Acad Sci U S A. 2006;103:10660–5.

9. Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wooterspoon A, Saffery C, Middleton G, Wadley J, et al. Epirubicin, oxaliplatin, and capcitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14:481–9.

10. Wang X, He C, Hu X. LIM homeobox transcription factors, a novel subfamily which plays an important role in cancer (Review). Oncol Rep. 2014;31:1975–85.

11. Wang Y, Li Y, Guo C, Lu Q, Wang W, Jia Z, Chen P, Ma K, Reinberg D, Zhou C. ISL1 and JMJD3 synergistically control cardiac differentiation of embryonic stem cells. Nucleic Acids Res. 2016;44:6741–55.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.